Tirzepatide, Morbidity & Mortality in Obesity: Pioneering a Holistic Approach to Obesity Outcomes Trials

Time: 8:30 am
day: Day One


  • Investigating an unprecedented step forward in weight loss: development of the dual GIP and GLP-1 receptor agonist tirzepatide
  • Moving beyond traditional outcome trials for individual indications to efficiently assess efficacy in obesity, HFpEF, NASH, CKD, and other obesity-related morbidities
  • Navigating a broader primary endpoint and select type-1 error controlled secondary endpoints to study multiple outcomes in select populations